Omrix Biopharmaceuticals Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
212
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$458M
- Investors
-
1
Omrix Biopharmaceuticals General Information
Description
Developer and manufacturer of products derived from human plasma. The company develops hemostatic products designed to control bleeding during surgery and immunotherapy
Contact Information
Corporate Office
- One Rockefeller Center
- Suite 2322
- New York, NY 10020
- United States
Corporate Office
- One Rockefeller Center
- Suite 2322
- New York, NY 10020
- United States
Omrix Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 30-Dec-2008 | $458M | Completed | Generating Revenue | ||
| 8. IPO | 21-Apr-2006 | Completed | Generating Revenue | |||
| 7. Mezzanine | 01-Apr-2005 | Completed | Generating Revenue | |||
| 6. Debt - General | 01-Mar-2005 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 01-Feb-2005 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 05-Aug-2004 | Completed | Product Development | |||
| 3. Later Stage VC (Series A) | 22-Mar-2001 | Completed | Product Development | |||
| 2. Early Stage VC | 04-Sep-1999 | $20M | $35.2M | Completed | Product Development | |
| 1. Early Stage VC | 01-Jan-1998 | $15.2M | $15.2M | Completed | Product Development |
Omrix Biopharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Omrix Biopharmaceuticals Patents
Omrix Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2282847-A1 | Process and apparatus for coating a porous substrate with a coating liquid | Active | 22-May-2008 | ||
| EP-2282847-B1 | Process for coating a porous substrate with a coating liquid | Active | 22-May-2008 | ||
| ES-2557175-T3 | Process for coating a porous substrate with a coating liquid | Active | 22-May-2008 | ||
| EP-2124063-A1 | Protein assay | Active | 22-May-2008 | ||
| EP-2124063-B1 | Protein assay | Inactive | 22-May-2008 | C12Q1/56 |
Omrix Biopharmaceuticals Signals
Omrix Biopharmaceuticals Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BRM Group | Venture Capital | Minority | ||
| Capricorn Partners | Venture Capital | Minority | ||
| Carlyle AlpInvest | PE/Buyout | Minority | ||
| Catalyst Investments | PE/Buyout | Minority | ||
| Catalyst Venture Partners | Venture Capital | Minority |
Omrix Biopharmaceuticals FAQs
-
When was Omrix Biopharmaceuticals founded?
Omrix Biopharmaceuticals was founded in 1995.
-
Where is Omrix Biopharmaceuticals headquartered?
Omrix Biopharmaceuticals is headquartered in New York, NY.
-
What is the size of Omrix Biopharmaceuticals?
Omrix Biopharmaceuticals has 212 total employees.
-
What industry is Omrix Biopharmaceuticals in?
Omrix Biopharmaceuticals’s primary industry is Biotechnology.
-
Is Omrix Biopharmaceuticals a private or public company?
Omrix Biopharmaceuticals is a Private company.
-
What is the current valuation of Omrix Biopharmaceuticals?
The current valuation of Omrix Biopharmaceuticals is .
-
What is Omrix Biopharmaceuticals’s current revenue?
The current revenue for Omrix Biopharmaceuticals is .
-
How much funding has Omrix Biopharmaceuticals raised over time?
Omrix Biopharmaceuticals has raised $87.5M.
-
Who are Omrix Biopharmaceuticals’s investors?
BRM Group, Capricorn Partners, Carlyle AlpInvest, Catalyst Investments, and Catalyst Venture Partners are 5 of 8 investors who have invested in Omrix Biopharmaceuticals.
-
When was Omrix Biopharmaceuticals acquired?
Omrix Biopharmaceuticals was acquired on 30-Dec-2008.
-
Who acquired Omrix Biopharmaceuticals?
Omrix Biopharmaceuticals was acquired by Johnson & Johnson.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process